like many many other drugs do, that should be a known thing for investors. However, off-label prescription is a common practice among doctors when they see the drug is good for their patients. That's why in "Biotech Stock Mailbag" today, when mentioning Aegerion and Isis drugs, Adam Feuerstein writes:
"I don't expect FDA to mandate genotyping to ensure that all patients have true HoFH. This means use of both drugs could bleed into heterozygous familial hypercholesterolemia (HeFH) patients."
Even if just for one thousand HeFG patients, Adam believes:
"One thousand patients on lomitapide at $300,000 per year are enough to justify significant upside to Aegerion's current stock price. "
Let lone more approval is coming from Europe early next year.
Adam is a senior Biotech stock analyst who writes Biotech Stock Mailbag on a regular basis for many years. Should investors be heeding him?